Evelo’s Phase II Data Suggest Strong Position In Mild-To-Moderate Psoriasis
Executive Summary
Analysts say biotech’s EDP1815 may offer similar efficacy to Amgen’s Otezla, with better safety. Evelo says data offer new proof for its small intestinal axis approach to inflammatory disease.
You may also be interested in...
Union Inks China Deal For Promising Skin Drug Orismilast
Innovent is paying the Danish biotech $20m upfront for the China rights to the mid-stage PDE4 inhibitor that is being developed for psoriasis, atopic dermatitis and hidradenitis suppurativa.
US FDA Restricts JAK Inhibitors To Second-Line In Rheumatoid Arthritis Amid CV, Cancer, Mortality Risks
Now that the analysis of Pfizer’s postmarketing trial for Xeljanz is complete, though, application reviews of other products will likely be completed. The Xelijanz study revealed elevated risk of heart-related events, cancer, blood clots and death, resulting in a class-wide indication restriction and a revised boxed warning.
Amgen Continues To Feel COVID-19 Sales Impact In Q1
Patients’ COVID-19 anxiety continues to keep them from seeking treatments for psoriasis, migraine and even cancer, Amgen said, blaming the pandemic for much of its 4% decline in first quarter revenue.